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Intellectual Property
This section is devoted to giving readers an inside 
view of the crossing point between intellectual prop-
erty (IP) law and risk regulation. In addition to up-
dating readers on the latest developments in IP law 
and policies in technological ields (including chemi-
cals, pharmaceuticals, biotechnology, agriculture and 
foodstuffs), the section aims at verifying whether such 
laws and policies really stimulate scientiic and tech-
nical progress and are capable of minimising the risks 
posed by on-going industrial developments to indi-
viduals’ health and safety, inter alia.
The Case of Plain Packaging 
of Cigarettes
Alberto Alemanno* and Enrico Bonadio**
In a bid to reduce smoking rates, Australia is set to 
become the irst country in the world to introduce 
legislation requiring “plain packaging” for cigarettes. 
“Plain packaging” (also known as “generic packag-
ing”) means that all forms of tobacco branding are 
required to be labelled exclusively with simple una-
dorned text. This means that trademarks, graphics 
and logos are removed from cigarette packs with the 
exception of the brand name which is displayed in 
a standard font. By standardising the appearance of 
all cigarette boxes, plain packaging aims to make all 
packs look unattractive and render health warnings 
more prominent.
This legislative move by Australia inds its origin 
in the National Health Taskforce discussion paper 
issued in 20081, which put forth recommendations 
on how to address a number of health issues over 
the next decade. The stated goal of the plain packag-
ing, as recently enshrined by the Australian Federal 
Government, is (a) to curb the initiation of tobacco 
use, reduce tobacco consumption and incidences of 
relapse in those who quit smoking; (b) to enhance the 
effectiveness of package warnings; and (c) to remove 
the power of the packaging to mislead and deceive 
consumers.
Australia is not alone. The United Kingdom, Can-
ada and New Zealand are also considering laws for 
making this marketing restriction mandatory.
However, plain packaging raises both health-relat-
ed and legal tricky issues. Indeed, it is being persist-
ently challenged not only by the tobacco industry 
as to its legality, but also its genuine effectiveness 
for public health in reducing tobacco consumption 
levels.
On the one hand, supporters of generic packaging 
argue that this innovative way of marketing cigarette 
packs would make them look not only less attractive 
but also contribute to make health warnings (“Smok-
ing can kill you”) more visible. Warnings on plain 
white packages may be more effective at grabbing 
attention and enhancing recall than warnings on 
regular packages.
On the other hand, tobacco companies argue that 
generic packaging would not be very effective in 
serving the stated purpose of reducing smoking and 
protecting human health. To support this claim, they 
often refer to the lack of evidence proving that generic 
packaging (i) makes cigarette boxes less attractive to 
consumers and health warnings and renders the infor-
mation more visible and (ii) as a result induces smoking 
cessation2. Plain packaging could even increase smok-
ing uptake – it is argued – because companies would 
be prompted to compete on the basis of cigarette prices 
only. This would make tobacco cheaper and more af-
* Associate Professor, HEC Paris, France.
** Lecturer, University of Abertay Dundee, United Kingdom.
1 The report is available on the Internet at <http://www.preventative-
health.org.au/internet/preventativehealth/publishing.nsf/Content/
discussion-technical-1> (last accessed on 7 July 2010).
2 In a 1995 report entitled “The Tobacco Industry and the Costs of 
Tobacco-Related Illness” (released by the Australian Senate Com-
munity Affairs References Committee) the following conclusion 
was reached: “The Committee received a range of often conlict-
ing evidence on the eficacy of generic packaging. While some 
evidence suggested that generic packaging would reduce the at-
tractiveness of cigarettes for children, other evidence raised some 
doubts concerning the effectiveness of this approach. The Com-
mittee believes that more research needs to be undertaken into the 
role generic packaging could play in an integrated strategy address-
ing the problem of adolescent smoking. The Committee considers 
that, on the basis of the evidence received, there is not suficient 
evidence to recommend that tobacco products be sold in generic 
packaging.” (para. 3.54). The report is available on the Internet at 
<http://www.plain-packaging.com/Australia> (last accessed on 7 
July 2010). Moreover, in the UK Parliamentary session of 25 June 
2009 the Minister of State for Public Health, Ms Gillian Merron, 
was reported to have said: “There is some evidence that branding 
on cigarette packs may increase brand awareness among young 
people but it is not conclusive. […] While there is also evidence to 
suggest that branding on packs may mislead customers about the 
relative safety of different tobacco products, that too is very limited. 
No studies have been undertaken to show that plain packaging of 
tobacco would cut smoking uptake among young people or en-
able those who want to quit to do so. Given the impact that plain 
packaging would have on intellectual property rights, we would 
undoubtedly need strong and convincing evidence of the beneits 
to health, as well as its workability, before this could be promoted 
and accepted at an international level – especially as no country in 
the world has introduced plain packaging”. This excerpt is avail-
able on the Internet at <http://www.publications.parliament.uk/
pa/cm200809/cmpublic/health/090625/pm/90625s09.htm> (last 
accessed on 7 July 2010).
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fordable for consumers, particularly amongst young 
people. As alternative, it is believed that other less in-
vasive instruments than generic packaging would be 
far more effective in the struggle against smoking, for 
example, educational campaigns, health information 
and warnings on cigarette boxes, etc.
Moreover, according to Big Tobacco, plain pack-
aging represents an encroachment on the rights 
of trademark owners and their ability to use their 
trademarks properly and lawfully. Indeed, the most 
threatening argument used against plain packaging 
consists in its alleged incompatibility with WTO law. 
In particular, such a marketing restriction might turn 
out to contravene TRIPs provisions on trademarks, 
thus triggering a dispute before the WTO dispute set-
tlement adjudication bodies. Critics argues that plain 
packaging would violate several TRIPs trademark-re-
lated provisions, i.e. Articles 17, 20 and 15(4) TRIPs 
and Article 6-quinquies (B) Paris Convention, which 
is incorporated by reference into TRIPs pursuant to 
its Article 2(1)3.
One of the most relevant questions concerning the 
alleged TRIPs-incompatibility of generic packaging 
relates to Article 8(1) TRIPs.
This provision states that “Members may, in formu-
lating or amending their laws and regulations, adopt 
measures necessary to protect public health and nutri-
tion, and to promote the public interest in sectors of 
vital importance to their socio-economic and techno-
logical development, provided that such measures are 
consistent with the provisions of this Agreement.”
It should be noted that any WTO Member State 
seeking to adopt a measure (e.g. a public health meas-
ure) pursuant to Article 8(1) should prove inter alia 
that this is (i) necessary for the promotion of the 
public interest in sectors of vital importance (e.g. to 
protect human health) and (ii) consistent with the 
TRIPs Agreement4.
The irst requirement, i.e. a necessity test, is two-
fold. A causal link needs to be established between 
the measure and the protection of the speciic public 
interest, and then the measure should be the least 
restrictive on intellectual property rights (IPRs). The 
scope of this provision is further limited by the sec-
ond abovementioned requirement, i.e. that the meas-
ure be compatible with the TRIPs Agreement.
First, plain packaging could fail to satisfy the 
abovementioned causal link requirement. Because of 
the uncertainty surrounding its inherent ability and 
effectiveness to reduce the incidence of smoking, it 
might be dificult for states seeking to adopt generic 
packaging to prove the existence of a causal relation-
ship between such a measure and the protection of 
public health. In addition, plain packaging would 
appear to be unlikely to satisfy the necessity test for 
a further reason. As shown above, there might in-
deed be other means of attaining the same public 
health objective that would be more effective and less 
restrictive of IPRs, such as educational campaigns, 
health information and warnings as well as advertis-
ing restrictions.
Finally, it is not an easy matter to meet the sec-
ond condition of Article 8(1) – i.e. consistency of the 
measure in question with TRIPs. Thus a Panel’s deci-
sion inding generic packaging is contrary to TRIPs 
cannot be ruled out.
Nevertheless, states willing to adopt plain packag-
ing may overcome the abovementioned dificulties if 
they succeed in proving (a) the existence of the caus-
al link between this marketing restriction and the 
protection of public health (e.g. by relying on studies 
conirming that this measure would make cigarette 
boxes less attractive to consumers and health warn-
ings and information more visible and accordingly 
increase the incidence of smoking cessation); and (b) 
that there exists no less trade-restrictive means of 
achieving the chosen policy goal. In addition, states 
should also prove that plain packaging is compli-
ant with TRIPs. In this respect, particular weight 
should be attached to both Article 8.1 TRIPs and 
paragraph 4 of the 2001 Doha Declaration on the 
TRIPS Agreement and Public Health. In particular the 
latter reproduces the spirit of the former by stress-
ing that “the TRIPs Agreement does not and should 
not prevent members from taking measures to protect 
public health”5.
Plain packaging is a thorny issue that is likely to 
keep busy IPRs and WTO specialists as well as aca-
demics in the years to come.
3 For a irst analysis of the compatibility of plain packaging with the 
trademark-related provisions of the TRIPs Agreement see Benn Mc-
Grady, “TRIPs and Trademarks: The Case of Tobacco”, 3(1) World 
Trade Review (2004), pp. 53–82.
4 See Nuno Pires de Carvalho, The TRIPs Regime of Patent Rights 
(The Hague: Kluwer 2005), pp. 119 et sqq.
5 The Doha Declaration on the TRIPS Agreement and Public health 
was adopted on 14 November 2001 by the WTO Ministerial Con-
ference. States seeking to adopt plain packaging should also stress 
that each country has the right to decide the level of health pro-
tection that it considers appropriate in a given situation, as it was 
stated by the WTO Panel in EC – Asbestos, see European Com-
munities – Measures Affecting Asbestos and Asbestos-Containing 
Products, Report of the Appellate Body, WTO Doc. WT/DS135/
AB/R, 5 April 2001, at para. 168.
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As shown above, the tobacco industry is partic-
ularly keen to emphasize both the futility of plain 
packaging for reducing smoking rates and its in-
compatibility with TRIPs provisions on trademarks. 
Clearly, major tobacco companies fear to lose a pow-
erful means of communication between themselves 
and their consumers and are afraid that what they 
see as a serious curtailment of their trademark and 
goodwill-related rights could hit their lourishing 
businesses hard and decrease cigarette sales. Indeed, 
it is a fact that sales of tobacco products continue to 
rise worldwide. For example, some igures revealed 
that tobacco sales in UK rose to £11.3 billion in 2009, 
an increase of 3.3 % on the previous year6. Moreo-
ver, the World Health Organization found that the 
developing world tobacco consumption is rising by 
3.4 % per year7.
On the other hand, those who support plain 
packaging stress its enormous potential in the ight 
against tobacco-related diseases and defend its legal-
ity and conformity with WTO law and particularly 
with international provisions protecting trademarks. 
In their eyes, plain packaging is both useful and law-
ful.
Given the high economic stakes related to the in-
troduction of plain packaging and the impact that 
such measure could have on tobacco consumption, 
it is not unlikely that any state that adopts such a 
marketing restriction will expose themselves to a 
WTO dispute settlement proceedings. Needless to 
say, such actions might be triggered by countries 
particularly keen in protecting their tobacco majors. 
Yet, the outcome of such a dispute would be uncer-
tain and – as is often the case – technical expertise 
is likely to make the difference. What is the impact 
of plain packaging on consumer’s choice and tobacco 
consumption? There does not seem to be any deini-
tive answer yet.
Nanotechnology
This section is meant to give readers an insight into 
the emerging ield of nanotechnologies and risk regu-
lation. It informs and updates readers on the latest 
European and international developments in nanote-
chnologies and risk regulation across different sectors 
(e.g., chemicals, food, cosmetics, pharmaceuticals) 
and policy areas (e.g., environmental protection, oc-
cupational health and consumer product, food and 
drug safety). The section analyzes how existing regula-
tory systems deal with new kinds of risks and reviews 
recent regulatory developments with a focus on how 
best to combine scientiic freedom and technological 
progress with a responsible development and com-
mercialization of nanotechnologies.
Nanomaterial Safety: 
The Regulators’ Dilemma
Nico Jaspers*
I. Introduction
Nanotechnologies have been hyped as bringing 
about another industrial revolution. But they have 
also caused concern about their potential adverse 
effects on human health and the environment, mis-
use for military purposes, and excessive corporate 
control of intellectual property. Policy-makers ind 
themselves in the dificult position of promoting 
the development of nanotechnologies while at the 
same time securing public trust in their safe com-
mercial application. Having invested enormous 
inancial resources into nanotechnology research 
and development,1 policy-makers often struggle 
to convince an increasingly informed – and some-
times sceptical – public that existing regulatory 
frameworks are suficiently able to address po-
tential risks related to nanotechnologies. In most 
cases, this is not for lack of want or interest, but due 
to the challenge of framing “nano” for regulatory 
purposes. Regulators face a dilemma: they have to 
ensure the safety of nano technology applications 
without being able to state exactly what nanotech-
nology is.
6 See News.Scotsman.com of 21st February 2010.
7 See the relevant smoking statistics available on the Inter-
net at <http://www.wpro.who.int/media_centre/fact_sheets/
fs_20020528.htm> (last accessed on 7 July 2010).
* London School of Economics, United Kingdom. Please send in-
quiries to n.jaspers@lse.ac.uk.
1 Cientiica, “Nanotechnology Takes a Deep Breath … and Prepares 
to Save the World!”, Cientiica Report (2009).
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